

FOR IMMEDIATE RELEASE



August 12, 2013

AnGes MG, Inc.

### **Results of Vical's Phase III Trial of Allovectin®**

AnGes MG, Inc. ("AnGes") announced the results of a Phase III trial of Allovectin® in metastatic melanoma conducted by Vical, Inc. ("Vical") in the United States (US) as follows.

In its August 12, 2013 press release, Vical announced that the Allovectin® Phase III trial failed to demonstrate a statistically significant improvement in both the primary and secondary efficacy endpoints. Mr. Samant, CEO of Vical, said the company will terminate development of the project.

As a result, AnGes expects no future royalties from Allovectin®. AnGes will carry out strategic measures against development of its projects, including Collatogene®.

There will be no effect on the consolidated business performance for the fiscal year ending in December 2013.

###

*Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.*

<p>AnGes MG, Inc. Corporate Communications TEL: +81-3-5730-2641, FAX: +81-3-5730-2635 <a href="http://www.anges-mg.com">http://www.anges-mg.com</a> Email: <a href="mailto:info@anges-mg.com">info@anges-mg.com</a></p>
---